Investment Thesis
Eli Lilly demonstrates exceptional fundamental strength with 44.7% revenue growth and 94.9% net income growth, indicating accelerating business momentum and operating leverage expansion. Outstanding profitability metrics (31.7% net margin, 39.5% operating margin) combined with robust free cash flow generation ($15.5B, 23.7% FCF margin) and strong balance sheet metrics (143.3x interest coverage) reveal a company firing on all operational cylinders.
LLY Strengths
- Exceptional revenue growth of 44.7% YoY demonstrates strong market demand and successful product pipeline execution
- Net income growth of 94.9% significantly outpaces revenue growth, indicating superior operational leverage and margin expansion
- Outstanding profitability with 31.7% net margin and 39.5% operating margin among the highest in pharmaceuticals
- Robust free cash flow generation of $15.5B (23.7% FCF margin) provides substantial capital for R&D, dividends, and debt reduction
- Fortress balance sheet with 143.3x interest coverage ratio and $7.3B cash position despite $40.9B debt
- Exceptional returns with 77.8% ROE and 18.4% ROA indicating efficient capital deployment
- Strong current ratio of 1.58x and quick ratio of 1.19x demonstrate solid short-term liquidity
LLY Risks
- High leverage with 1.54x debt-to-equity ratio requires careful monitoring, though offset by exceptional interest coverage
- Pharmaceutical industry subject to regulatory, patent expiration, and pricing pressure risks that could impact future growth sustainability
- Heavy reliance on product pipeline success; any major pipeline failure could significantly impact future revenue and margin trajectory
- 44 insider Form 4 filings in 90 days warrants investigation for potential signaling of executive confidence or concern
Key Metrics to Watch
- Organic revenue growth sustainability and pipeline advancement progress
- Maintenance of operating and net margins as revenue scales
- Free cash flow conversion and capital allocation priorities
- Debt reduction trajectory relative to cash generation capacity
- R&D productivity and success rates of clinical trials in development
LLY Financial Metrics
Revenue
$65.2B
Net Income
$20.6B
EPS (Diluted)
$22.95
Free Cash Flow
$15.5B
Total Assets
$112.5B
Cash Position
$7.3B
LLY Profitability Ratios
Gross Margin
N/A
Operating Margin
39.5%
Net Margin
31.7%
ROE
77.8%
ROA
18.4%
FCF Margin
23.7%
LLY Balance Sheet & Liquidity
Current Ratio
1.58x
Quick Ratio
1.19x
Debt/Equity
1.54x
Debt/Assets
0.0%
Interest Coverage
143.27x
Long-term Debt
$40.9B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI